Reading Time: 5 minutesVictoria Pugh is studying for her PhD at the Universities of Bradford and Reading, which is funded by the MND Association. Under the leadership of Prof
Category: Treatments
Reading Time: 3 minutesAfter we posted yesterday’s blog (Thursday 10 October) about Giovanna Mallucci’s research in Leicester, we received a report on the story from the President of the
Reading Time: 4 minutesThe only ‘proven’ treatment to slow the progression of MND is Riluzole. There are, however, many organisations offering expensive ‘unproven’ and ‘alternative’ treatments for MND.
Reading Time: 4 minutesAfter a brilliant first day at ENCALS, which included a talk by Dr Johannes Brettschneider, the second day began with a talk by Thierry Latran
Reading Time: 2 minutesThe National Institute for Health Research (NIHR) has launched their ‘It’s OK to ask campaign’ which encourages patients and the public to ask about clinical research.
Reading Time: 3 minutesI have recently updated the clinical trials section of our website with a couple of MND clinical trials that are currently recruiting. This has led me to
Reading Time: 3 minutesResults from a phase I clinical trial of a drug known as ISIS 333611 have been published open-access online in the scientific journal Lancet Neurology on
Reading Time: 3 minutesA very much ‘must report on’ session of the 23rd International Symposium on ALS/MND was the clinical trials and trial design session. There are many
Reading Time: 4 minutesA collaborative American research group, led by Prof Aaron Gitler from Stanford University School of Medicine in California, has identified a potential therapeutic target for
Reading Time: 3 minutesPromising results from a Phase II clinical trial for a drug called NP001 have been announced by the biopharmaceutical company Neuraltus. The trial, conducted in America, suggested